Staar Surgical Co. Stock
Staar Surgical Co. Stock
Pros and Cons of Staar Surgical Co. in the next few years
Pros
Cons
Performance of Staar Surgical Co. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | 0.970% | -3.460% | -4.986% | -30.108% | 47.055% | -61.120% | - |
Orasure Tech | -0.980% | 2.642% | -8.182% | -18.548% | -32.215% | -32.306% | -41.827% |
scPharmaceuticals | -3.170% | 0.943% | -6.550% | -58.039% | -25.565% | -11.203% | - |
SI-BONE Inc | -3.700% | -2.985% | -7.143% | -39.815% | -31.579% | -51.128% | - |
Comments
News
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today